2,540 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Morningstar Investment Management LLC

Key Points

• Morningstar Investment Management LLC has purchased 2,540 shares of Thermo Fisher Scientific, valued at approximately $1,030,000, indicating continued institutional interest in the company.
• Thermo Fisher reported earnings of $5.36 EPS for the last quarter, surpassing analysts' expectations and demonstrating a 2.9% year-over-year revenue increase to $10.86 billion.
• The consensus rating for Thermo Fisher stock is currently categorized as a "Moderate Buy", with an average price target of $589.10

Morningstar Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 2,540 shares of the medical research company's stock, valued at approximately $1,030,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the last quarter. Root Financial Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 5.0% during the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock worth $252,000 after buying an additional 24 shares during the last quarter. Rossmore Private Capital lifted its position in Thermo Fisher Scientific by 0.5% in the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company's stock valued at $2,315,000 after purchasing an additional 24 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH lifted its position in Thermo Fisher Scientific by 3.1% in the second quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company's stock valued at $326,000 after purchasing an additional 24 shares during the period. Finally, Somerville Kurt F lifted its position in Thermo Fisher Scientific by 1.6% in the second quarter. Somerville Kurt F now owns 1,605 shares of the medical research company's stock valued at $651,000 after purchasing an additional 25 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO stock opened at $524.80 on Tuesday. The firm has a 50 day moving average of $489.83 and a 200-day moving average of $447.66. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market cap of $198.17 billion, a price-to-earnings ratio of 30.35, a PEG ratio of 2.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the firm earned $5.37 EPS. The company's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on TMO shares. Weiss Ratings restated a "hold (c-)" rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research report on Thursday, October 9th. UBS Group raised their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Finally, Raymond James Financial reiterated an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $589.10.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company's stock, valued at approximately $56,937,881. The trade was a 0.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.